GO:0001946 lymphangiogenesis: Genes, Functions & Methods

Lymphangiogenesis, formally annotated as GO:0001946, is the biological process by which new lymphatic vessels form from pre-existing vessels. This process is fundamental to lymphatic system development and function, governing interstitial fluid drainage, immune surveillance, and lipid uptake. Unlike angiogenesis, which produces blood vessels, lymphangiogenesis generates vessels specialized for unidirectional lymph transport, a distinction that has driven decades of research into its molecular regulation. The importance of lymphangiogenesis extends across physiology and pathology. During embryonic development, lymphatic vessels arise from venous endothelial cells that commit to a lymphatic fate, a process controlled by transcription factors such as PROX1 and signaling through VEGFR3. In adults, lymphangiogenesis is largely quiescent but can be reactivated in wound healing, inflammation, and tumor progression. Dysregulated lymphangiogenesis is implicated in cancer metastasis, where tumor-associated lymphatics provide routes for cancer cell dissemination, and in cardiovascular disease, where cardiac lymphangiogenesis can be protective or maladaptive depending on context. In the cornea, lymphangiogenesis contributes to pathological states such as transplant rejection and inflammation. Aging also modulates lymphangiogenesis, with emerging evidence linking lymphatic dysfunction to aging-associated diseases. Understanding the cellular and molecular mechanisms of lymphangiogenesis is therefore critical for developing targeted therapies. Researchers study this process using in vitro and in vivo models, including lymphatic endothelial cell culture, sprouting assays, and genetic mouse models. The field continues to benefit from advances in imaging, single-cell transcriptomics, and CRISPR-based genome editing, which allow precise manipulation of genes involved in lymphatic vessel formation.

According to the Gene Ontology, lymphangiogenesis (GO:0001946) is defined as lymph vessel formation when new vessels emerge from the proliferation of pre-existing vessels. This definition distinguishes lymphangiogenesis from de novo lymph vessel formation (lymphvasculogenesis) and from angiogenesis, which pertains to blood vessels. The term encompasses the sprouting, migration, proliferation, and differentiation of lymphatic endothelial cells, as well as the subsequent remodeling and maturation of newly formed lymphatic capillaries and collecting vessels.

Lymphangiogenesis is critically important because it governs fundamental physiological processes and is implicated in numerous diseases. The lymphatic system maintains tissue fluid balance, transports dietary lipids, and facilitates immune cell trafficking. When lymphangiogenesis is dysregulated, it contributes to cancer progression by providing routes for lymphatic metastasis, to cardiovascular disease where cardiac lymphangiogenesis can influence heart failure outcomes, and to ocular pathologies such as corneal inflammation and transplant rejection. Moreover, aging is associated with changes in lymphangiogenesis that may exacerbate age-related diseases. Understanding the molecular mechanisms of lymphangiogenesis is therefore essential for developing therapeutic strategies targeting lymphatic vessel formation in cancer, cardiovascular disease, and other conditions.

The following genes and proteins are central to lymphangiogenesis, as supported by published literature.

Lymphangiogenesis is tightly regulated at multiple levels. Transcriptional regulation involves PROX1, SOX18, COUP-TFII, and FOXC2, which control LEC fate and maturation. Growth factor signaling through VEGFC/VEGFR3 is the principal extracellular regulatory axis, modulated by co-receptors such as NRP2 and proteases like CCBE1 and ADAMTS3. Intracellular signaling pathways including PI3K/AKT, MAPK/ERK, and Rho GTPases regulate LEC proliferation, migration, and sprouting. In pathological contexts, immune cells and tumor microenvironment factors, such as ETV4-mediated neutrophil infiltration, can enhance lymphangiogenesis. Additionally, mechanical forces and extracellular matrix stiffness influence LEC behavior and vessel remodeling. Aging is associated with altered lymphangiogenesis, potentially through changes in growth factor availability and immune cell function.

Lymphangiogenesis is a critical step in cancer metastasis, as tumor-associated lymphatic vessels provide a route for cancer cell dissemination to regional lymph nodes and distant organs. In gastric cancer, lymphangiogenesis correlates with lymph node metastasis and poor prognosis. Tumor cells secrete lymphangiogenic factors such as VEGFC and VEGFD, which stimulate LEC proliferation and sprouting. In bladder cancer, ETV4-mediated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis, highlighting the role of the immune microenvironment. Targeting lymphangiogenesis is therefore a potential therapeutic strategy to inhibit metastasis.

Cardiac lymphangiogenesis plays a significant role in heart disease. In pressure-overload-induced heart failure, lymphangiogenesis is activated and can be protective by reducing myocardial edema and improving cardiac function. However, excessive or dysregulated lymphangiogenesis may also contribute to adverse remodeling. Therapeutic modulation of cardiac lymphangiogenesis, for example by administering VEGFC, has shown promise in preclinical models of myocardial injury. These findings suggest that targeting lymphatic vessel growth could be a novel strategy for treating heart disease.

The cornea is normally avascular and alymphatic, but under pathological conditions such as inflammation, infection, or injury, lymphangiogenesis can occur. Corneal lymphangiogenesis contributes to transplant rejection, dry eye, and other ocular surface diseases. Guidance molecules such as SEMA3A and CXCL12/CXCR4 regulate corneal lymphangiogenesis, and their dysregulation can lead to pathological vessel growth. Understanding these mechanisms is important for developing therapies to preserve corneal transparency and improve transplant outcomes.

Aging is associated with changes in lymphangiogenesis that may contribute to aging-associated diseases. Declining lymphatic function can lead to impaired fluid clearance, increased inflammation, and reduced immune surveillance, which are hallmarks of aging. Emerging evidence suggests that modulating lymphangiogenesis could mitigate age-related pathologies, although the mechanisms remain under investigation.

In vitro models using primary lymphatic endothelial cells (LECs) or immortalized LEC lines are widely used to study lymphangiogenesis. Proliferation, migration, and tube formation assays can assess the effects of genetic manipulations. Sprouting assays from spheroids or aortic rings provide more physiologically relevant models. These assays are often combined with CRISPR knockout or overexpression to interrogate gene function.

Mouse models are essential for studying lymphangiogenesis in a physiological context. Corneal lymphangiogenesis assays allow visualization of vessel growth in a normally avascular tissue. Cardiac lymphangiogenesis can be studied in pressure-overload models or myocardial infarction models. Genetic mouse models, including knockouts and knock-ins, enable causal testing of candidate genes.

Advanced imaging techniques such as confocal microscopy, two-photon microscopy, and light-sheet microscopy allow visualization of lymphatic vessels in tissues. Immunostaining for LEC markers (LYVE1, PDPN, PROX1) is standard for identifying lymphatic vessels. Quantification of vessel density, sprouting, and branching is performed using image analysis software.

Single-cell RNA sequencing (scRNA-seq) has been used to identify LEC subpopulations and their heterogeneity in health and disease. Bulk RNA-seq of sorted LECs can reveal gene expression changes in response to genetic or pharmacological perturbations. Bioinformatics tools for pathway enrichment and gene regulatory network analysis help interpret these data.

Researchers studying lymphangiogenesis-related genes often need to determine whether a candidate gene is causally involved in lymphatic vessel formation, and CRISPR-based models provide the most direct approach. EDITGENE offers a comprehensive suite of services to support such studies, from knockout cell lines to library screening and bioinformatics analysis.

Lymphangiogenesis (GO:0001946) is a fundamental biological process with critical roles in development, tissue homeostasis, and disease. The molecular mechanisms involve a complex interplay of growth factors, transcription factors, and guidance cues that regulate lymphatic endothelial cell fate, sprouting, and maturation. Dysregulation of lymphangiogenesis contributes to cancer metastasis, cardiac disease, corneal pathology, and aging-associated disorders, highlighting its potential as a therapeutic target. Continued research using advanced models, including CRISPR-based genome editing, will further elucidate the regulatory networks and enable the development of targeted therapies for lymphatic-related diseases.